Literature DB >> 16458073

The immunosuppressive effects of ciprofloxacin during human mixed lymphocyte reaction.

Goutarou Katsuno1, Hideo Kohka Takahashi, Hiromi Iwagaki, Kenji Mizuno, Takahito Yagi, Shuji Mori, Shinya Saito, Tadashi Yoshino, Masahiro Nishibori, Noriaki Tanaka.   

Abstract

Interleukin (IL)-18, which is elevated in the plasma during acute rejection after organ transplantation, is known to induce the expression of intercellular adhesion molecule (ICAM)-1, B7.1, B7.2, CD40 and CD40 ligand (CD40L) on monocytes, the production of interferon (IFN)-gamma and IL-12 and the proliferation of lymphocytes during the human mixed lymphocyte reaction (MLR). Ciprofloxacin (CIP), which is useful for the clinical treatment of infections due to its antibacterial properties after transplantation, was shown to suppress the IFN-gamma and IL-12 production, the lymphocyte proliferation and the ICAM-1, B7.1, B7.2 and CD40 expression on monocytes during MLR in the presence of IL-18. CIP also induced the production of prostaglandin (PG) E2. In order to determine whether the effects of CIP on the expression of the activation markers were due to CIP-dependent production of PGE2, we examined the effect of cyclooxygenase (COX)-2 and protein kinase A (PKA) inhibitors on the actions of CIP. Thereby, the inhibitors were found to abolish the actions of CIP. These results therefore suggest that CIP might exert its immune modulatory effects via the production of PGE2.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16458073     DOI: 10.1016/j.clim.2005.12.004

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Prophylactic ciprofloxacin treatment prevented high mortality, and modified systemic and intestinal immune function in tumour-bearing rats receiving dose-intensive CPT-11 chemotherapy.

Authors:  H Xue; C J Field; M B Sawyer; L A Dieleman; V E Baracos
Journal:  Br J Cancer       Date:  2009-04-28       Impact factor: 7.640

2.  Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei.

Authors:  Kay B Barnes; Karleigh A Hamblin; Mark I Richards; Thomas R Laws; Andreas Vente; Helen S Atkins; Sarah V Harding
Journal:  Antimicrob Agents Chemother       Date:  2017-06-27       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.